Close
Kate Lathrop, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Kate Lathrop, M.D.
Dr. Lathrop was named one of San Antonio’s Top Doctors for Women and San Antonio’s Top Doctors 2021 and 2026.
Gender
- Female
-
Credentials
Credentials
Certifications
- American Board of Internal Medicine/Medical Oncology
- American Board of Internal Medicine
Education
- Medical School: University of Texas Health Science Center at San Antonio
- Residency: University of Texas Health Science Center at San Antonio
-
Locations & Contact
Locations & Contact
Dr. Lathrop is terrific. She listens and explains. I always feel very confident that I got the best care possible.
Patient
-
Research & Publications
Research & Publications
Breast Cancer Treatment Delays in a Majority Minority Community: Is There a Difference?
Parsons, H. M., Lathrop, K. I., Schmidt, S., Mazo-Canola, M., Trevino-Jones, J., Speck, H. & Karnad, A. B.
J. Oncol. Pract. 11(2):e144-53 (2014). PMID: 25515722; PMCID: PMC4365298
Use of Milestones and Development of Entrustable Professional Activities in 2 Hematology/ Oncology Training Programs.
Shumway, N. M., Dacus, J. J., Lathrop, K. I., Hernandez, E. P., Miller, M. & Karnad, A. B.
J. Grad. Med. Educ. 7, 101-104 (2015). PMID: 26217433; PMCID: PMC4507897
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Kate Lathrop M.D.
S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Bre
This clinical trial aims to validate the results observed in I-SPY2 and will test if adding durvalumab to neoadjuvant chemotherapy can increase pCR rates, shift residual cancer burden to lower values and improve invasive breast cancer free survival in early-stage HRpositive MP2 cancers.
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Kate Lathrop M.D.
Phase 1 Clinical Trial of Avasopasem in Patients with Metastatic Hormone Receptor Positive Breast Cancer with Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
This is a single institution, non-randomized, phase 1 with a dose expansion clinical trial investigating the addition of a novel agent, Avasopasem (GC4419), in patients with hormonal receptor positive (HR+) metastatic breast cancer with progression while on treatment with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor and an aromatase inhibitor.